echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Exclusive interview! Speed up the construction of the integrated mode of pharmaceutical "production, research and development" its key 3 factors

    Exclusive interview! Speed up the construction of the integrated mode of pharmaceutical "production, research and development" its key 3 factors

    • Last Update: 2021-01-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, the domestic innovative drug species have been listed, how to successfully realize the commercialization of innovative drugs under the special domestic pharmaceutical environment, but also become a lot of pharmaceutical companies, research and development institutions face an important issue.
    with the development of technology and the evolution of innovation forms in the pharmaceutical industry, government policies play an important role in the construction of innovation platforms, and the special position of national demand in the innovation process is further highlighted.
    2.0 form of innovation in the environment of knowledge society is promoting the transformation of pharmaceutical innovation from "production and research" to "political, academic and research" and then to the coordinated development of "political, industry and research".
    , how can the pharmaceutical industry open the "political use of industry, research and research" vein, improve the conversion rate of clinical results? And promote the integration, modernization and internationalization of innovative pharmaceutical industry and research? In this regard, the Pharmaceutical Intelligence Network specifically invited industry experts - Chongqing Medical University School of Pharmacy Party Secretary Professor Feng Tao, guest of the "Pharmaceutical Intelligence Interview" column, to share the "political and industry research" (hereinafter referred to as the integration of industry and research) experience.
    of China's pharmaceutical enterprises in china's innovative drug research and development situation to generic drugs- based, really have innovative drug research and development capabilities of enterprises are not many.
    years, China's innovative drug research and development capabilities have made great progress, encouraged by a series of drug research and development policies.
    since 2013, the number of domestic innovative drug declarations has been on the rise in all but one of the years since 2016.
    As of now (December 8), according to the database of drug registration and acceptance, the number of applications for registration of 1 class of innovative drugs in China in 2020 reached 1143, classified according to pharmacology, mainly in the field of anti-tumor, digestive system and cardiovascular system and other fields.
    Pication source: Pharmaceutical intelligence data" Although the domestic form of innovative drugs is a good one, but there are still some shortcomings, such as the domestic pharmaceutical industry research and development there is a common phenomenon: quick success, lack of original innovation ability.
    more generic drugs and fewer innovative drugs at the source.
    " Professor Feng Tao said, medicine as a special commodity, related to the health of the people, must be done by the system of professional institutions, professionals.
    In recent years, the strategic layout of many pharmaceutical companies is not long-term, lack of continuous innovation ability, universities or research institutions, only "research for research", resulting in repeated loss of industry innovation results, "accelerate the pharmaceutical 'production, research and development' integration model construction, it is very necessary."
    "Pharmaceutical" production, research and development" integration of 3 key points in Professor Feng Tao's view, the domestic pharmaceutical industry "production, research and development" system disobedient problem is very serious, to investigate its root cause, the first is the industry's lack of understanding of scientific classification, technical science and application Scientifically speaking, it should not be divided into stages by the three words of production, study and research, it is one in itself, and the second is that some pharmaceutical companies do not know the law of scientific development clearly, ignoring the law of scientific development with the times, not only enterprises, including universities, research and development institutions are not deep enough.
    "should not be 'headache, foot pain', but from the nature of development to understand the problem, in order to seize the essence of the development of the pharmaceutical industry."
    ," Professor Feng Tao said.
    the rapid development of innovative pharmaceutical biotechnology, requiring the pharmaceutical industry must be "production, research and development" integration, "has reached the point of urgency!" Professor Feng Tao said.
    gives his opinion on how to integrate production and research effectively.
    First, from the pharmaceutical enterprises, research and development institutions, drug innovation technology must match the speed of social development, so that research and development can keep up with the pace of development;
    , from a policy, it is recommended that relevant government departments establish reasonable policies to encourage innovative drug research and development.
    years, the state is actively promoting consistent evaluation, volume procurement and other pharmaceutical reform policies, forcing enterprises to transform, take the road of innovation and development, from a large generic drug to a large country of innovative drugs.
    the same time, the entry threshold of pharmaceutical enterprises should be raised, we should pay full attention to the ability of industry, science and research, in fact, only have the production capacity of pharmaceutical companies, the development of space and prospects are very limited.
    believe that in the future, with the active promotion of the state, the medical reform policy can be improved and the development of the pharmaceutical industry can be promoted.
    ," he said.
    Third, from the university, the scholars who do medical research should have market consciousness about their labor achievements, actively promote commercialization, not only for the material published in the paper, did not play its real value;
    from the current development of the status quo, focus on the development of biopharmaceuticals, can achieve corner over-car, change the situation in the original innovative drugs backward, the new crown vaccine research and development is a good example.
    university to help "production, research" integration is known, Chongqing Medical University School of Pharmacy was formally established in 2006.
    formed a "bachelor-master-doctoral-post-doctoral" complete pharmaceutical personnel training system, and become a university "production and research" integration demonstration base.
    , as party secretary of the College of Heavy Medicine, Professor Feng Tao gave a share of the university's achievements and experiences in the integration of "production, research and development".
    , in terms of personnel training, the College of Pharmacy has formed a "bachelor-master-doctoral-post-doctoral" complete pharmaceutical talent training system.
    its training, not only in improving the ability of talent, but also the overall quality of the individual training, "can not have knowledge, no culture."
    " second, the College of Heavy Medicine closely around the drug "research, development and application" of the three aspects of hard work, forming a basic research and new drug development of the same subject development pattern.
    have formulated support and guidance policies in the areas of achievement transformation and horizontal research.
    , for example, to assist enterprises to develop weight-loss drugs Oliste, innovative narcotic drugs EL-052, etc., to create economic benefits for enterprises hundreds of millions of dollars.
    Third, focus on establishing friendly and cooperative relations with domestic pharmaceutical enterprises, research institutes and pharmaceutical research institutions, have a strong platform for internships, build bridges between enterprises and universities, and promote the development of "production, research and development" in the pharmaceutical industry.
    Professor Feng Tao said that the pharmaceutical industry's "production, research and development" system effectively combined, not only in the efforts of universities, but also, the main body of the pharmaceutical market - pharmaceutical companies, research and development institutions and other social roles, to jointly help the development of the industry, promote the transformation of innovative drug achievements.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.